<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
[X] Quarterly Report Under Section 13 or 15(d) of The Securities Exchange
Act of 1934
For the quarterly period ended June 30, 2000
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from __________________ to ______________________.
Commission file number 333-19285
MPR HEALTH SYSTEMS, INC.
(formerly Myo Diagnostics, Inc.)
(Exact Name of Small Business Issuer as Specified in its Charter)
California 95-4089525
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
3710 South Robertson Boulevard
Culver City, California 90232
(Address of Principal Executive Offices)
(310) 559-5500
(Issuer's Telephone Number, Including Area Code)
Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for past 90 days.
Yes [X] No [ ]
State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date: Common Stock, no par value,
10,036,370 shares issued and outstanding as of June 30, 2000.
Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]
1
<PAGE> 2
MPR HEALTH SYSTEMS, INC.
INDEX TO FORM 10-QSB
<TABLE>
<CAPTION>
Page
----
<S> <C>
PART I FINANCIAL INFORMATION
Item 1. Financial Statements:
Balance Sheet (unaudited) as of June 30, 2000 3
Statements of Operations (unaudited) for the
Six months Ended June 30, 2000 and 1999 4
Statements of Cash Flows (unaudited) for the
Six months Ended June 30, 2000 and 1999 5
Notes to Financial Statements 7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 8
PART II OTHER INFORMATION
Item 1. Legal Proceedings 13
Item 2. Changes in Securities 13
Item 3. Defaults Upon Senior Securities 13
Item 4. Submission of Matters to a Vote of Security Holders 13
Item 5. Other Information 13
Item 6. Exhibits and Reports on Form 8-K. 13
</TABLE>
2
<PAGE> 3
PART I
FINANCIAL INFORMATION
Item 1. Financial Statements
MPR HEALTH SYSTEMS, INC.
BALANCE SHEET (Unaudited)
As of June 30, 2000
<TABLE>
<CAPTION>
June 30, 2000
-------------
<S> <C>
Current Assets
Cash $ 99,177
Accounts Receivable 263,365
Prepaid Expenses & Other Current Assets 42,948
-----------
Total current assets 405,490
Furniture & Equipment, net 117,780
Capitalized Product Development Costs 1,384,648
Other Assets 91,520
-----------
Total assets $ 1,999,438
Current Liabilities
Accounts Payable & Accrued Expenses 546,776
Current Portion of Leases Payable 8,830
-----------
Total Current Liabilities 555,606
Non Current Liabilities
Convertible Debenture Loans 167,000
Loans from Shareholder 14,000
Capital Leases Payable 14,750
Notes Payable 25,000
-----------
Total liabilities 776,356
Shareholders' Equity
Preferred stock, no par value
10,000,000 shares authorized
No shares issued and outstanding --
Common stock, no par value
50,000,000 shares authorized
10,036,370 shares issued and
outstanding 7,460,309
Paid in capital 319,650
Deficit accumulated during development stage (6,556,878)
-----------
Total Shareholders' Equity 1,223,081
-----------
Total Liabilities & Shareholders' Equity $ 1,999,438
</TABLE>
The accompanying notes are an integral part of these financial statements.
3
<PAGE> 4
MPR HEALTH SYSTEMS, INC.
STATEMENTS OF OPERATIONS (Unaudited)
For the Six Months Ended June 30, 2000 and 1999
<TABLE>
<CAPTION>
For the
Six Months Ended
June 30,
-------------------------
2000 1999
---------- ----------
<S> <C> <C>
Revenues $ 866,323 $ 36,136
Operating Expenses
Research & Development 65,324 34,320
Technical Services 110,677 49,898
Sales & Marketing 213,084 42,278
General & Administrative 378,558 175,218
---------- ---------
Total Operating Expenses 767,643 301,714
---------- ---------
Loss from Operations 98,680 (265,578)
Other Income (Expenses)
Interest Expense (8,770) (23,322)
Depreciation & Amortization (140,577) -
Miscellaneous (192) (14,536)
Interest Income - -
---------- ---------
Total Other Income (Expenses) (149,539) (37,858)
Provision for Taxes - -
---------- ---------
Income/(Loss) Before Extraordinary Item (50,860) (303,435)
---------- ---------
Net Income/(Loss) $ (50,860) $(303,435)
---------- ---------
Basic Earnings/(Loss) Per Share $ (0.01) $ (0.04)
---------- ---------
Diluted Loss Per Share $ (0.01) $ (0.04)
---------- ---------
Weighted Average Common Shares 9,876,620 7,219,870
</TABLE>
The accompanying notes are an integral part of these financial statements.
4
<PAGE> 5
MPR HEALTH SYSTEMS, INC.
STATEMENTS OF CASH FLOWS (Unaudited)
For the Six Months Ended June 30, 2000 & 1999
<TABLE>
<CAPTION>
For the
Six Months Ended
June 30,
--------------------------
2000 1999
---------- ----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss) $ (50,860) $(303,435)
Adjustments to Net Income (Loss):
Depreciation & Amortization 140,577 --
Extraordinary Loss on Debt Restruct
Bad Debt Expense -- --
Loss on Disposition of Fixed Assets
Stock Options Issued for
Services Rendered -- --
Common Stock Issued in Consideration
for Extension of Repayment Terms for
Notes Payable to Related Parties -- --
Common Stock Issued for Services
Rendered -- --
(Increase)/Decrease in:
Accounts Receivables (257,380) (9,000)
Other Receivables -- --
Prepaid Expenses (884) (7,500)
Employee Receivables
Other Assets (58,750) --
Increase/(Decrease) in:
Accounts Payable 35,501 (53,250)
Deferred Revenue (150,000)
Other Current Liabilities 82,501 (286,179)
--------- ---------
Net Cash Provided (Used) by
Operating Activities (259,296) (659,363)
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in Fixed Assets (79,452) --
Proceeds from Disposition of
Fixed Assets
Software Development Costs (2,192) --
--------- ---------
Net Cash Provided (Used) by
Investing Activities (81,644) --
</TABLE>
See accompanying notes and accountant's report.
5
<PAGE> 6
MPR HEALTH SYSTEMS, INC.
STATEMENTS OF CASH FLOWS (Unaudited)
For the Six Months Ended June 30, 2000 & 1999
<TABLE>
<CAPTION>
For the
Six Months Ended
June 30,
-------------------------
2000 1999
---------- ----------
<S> <C> <C>
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Bank Overdraft -- --
Issuance of Convertible Debentures -- --
Net Increase (Decrease) in Notes
Payables -- --
Net Increase (Decrease) in Notes
Payables to Related Parties -- --
Repayment (Borrowings) on Obligations
Under Capital Lease -- (27,701)
Net Proceeds from Issuance of
Common Stock 155,000 574,874
Increase (Decrease) in Paid-In Capital 3,250 --
--------- ---------
Net Cash Provided (Used) from
Financing Activities 158,250 547,173
--------- ---------
Prior Period Adjustment -- --
Net Increase (Decrease) in Cash (182,690) (112,190)
Beginning Cash 281,867 240,861
--------- ---------
Ending Cash $ 99,177 $ 128,671
--------- ---------
</TABLE>
6
<PAGE> 7
MPR HEALTH SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
1. Basis of Presentation and Significant Accounting Policies
The financial statements included herein have been prepared by MPR Health
Systems, Inc. (the "Company"), without audit, according to the rules and
regulations of the Securities and Exchange Commission. Certain information and
footnote disclosures normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such rules and regulations, although the Company believes
the disclosures that are made are adequate to make the information presented not
misleading. Further, the financial statements reflect, in the opinion of
management, all adjustments necessary to state fairly the financial position and
results of operations as of and for the periods indicated. These financial
statements should be read in conjunction with the Company's audited financial
statements and notes thereto as of and for the year ended December 31, 1999.
The financial statements have been prepared on the basis of the
continuation of the Company as a going concern. During the six months ended June
30, 2000, the Company had net loss of $50,860. The Company is in the early stage
of bringing the product to market as of June 30, 2000, and recovery of the
Company's assets is still dependent upon future events, the outcome of which is
indeterminable. Successful completion of the Company's development program and
its transition to the attainment of profitable operations is dependent upon
obtaining adequate financing to fulfill its development activities and achieving
a level of sales adequate to support the Company's cost structure. In view of
these matters, realization of a major portion of the assets in the accompanying
balance sheet is dependent upon the Company's ability to meet its financing
requirements and the success of its plans to sell its products. Further, the
results of operations for the six months ended June 30, 2000 are not necessarily
indicative of results to be expected for the full fiscal year ending December
31, 2000.
Until January 1, 2000 the Company had been a development stage company as
defined in Statement of Financial Accounting Standards ("SFAS") No. 7,
"Accounting and Reporting by Development Stage Enterprises." The Company is
devoting substantially all of its present efforts to establish its product
commercially and its planned principal operations are just commencing. All
losses accumulated since inception have been considered as part of the Company's
development stage activities.
7
<PAGE> 8
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
Until January 1, 2000 the Company has been a development stage company that
had not realized any material revenues. As of January 1 the Company launched its
product and its marketing plan in the U.S. and in foreign markets. Twenty-one
independent sales representatives were recruited and trained during the second
quarter and began making sales calls on key reference accounts in 43 states.
While this program has not had a material impact on revenues, initial contracts
are expected in the third quarter. An aggressive foreign technology-partnering
program was also initiated. An agreement was reached for exclusive distribution
in Ireland and the UK that provided the majority of the revenues in the first
half of 2000. Several additional strategic partnerships are also in discussion.
To support these programs, a detailed operations plan has been developed to
service the implementation of both foreign and domestic distribution. This plan
provides on-site training of administrative and technical personnel at the MPR
Center. These programs set the stage for growth in the second half of this year.
Forward Looking Statements
The Company may from time to time make "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. When used in
this discussion, the words "estimate", "project", "anticipate" and similar
expressions are subject to certain risks and uncertainties, such as changes in
general economic conditions, competition, changes in federal regulations, as
well as uncertainties relating to raising additional financing and acceptance of
the Company's product and services in the marketplace, including those discussed
below that could cause actual results to differ materially from those projected.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. The Company undertakes no
obligation to publicly release the results of any revisions to those
forward-looking statements which may be made to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
Results of Operations
Six months Ended June 30, 2000 as Compared to Six months Ended June 30,
1999. The Company generated revenues of $866,323 during the six months ended
June 30, 2000, as compared to revenues of $36,136 during the six months ended
June 30, 1999. This increase was due to revenues realized as a result of the
product launch. The foreign distribution agreement resulted in purchases of
report usage licenses, equipment and supplies, and amortization of annual
technology access fees that accounted for the buld of the first half sales.
The Company's operating expenses increased to $769,594 during the six
months ended June 30, 2000 from $284,622 during the six months ended June 30,
1999. The primary reason for the higher expenses over the same period in 1999 is
an increase in staff from six to ten as a result of the initiation of the
Company's sales and marketing plan. Travel expenses associated with the
recruitment of independent sales representatives was another significant factor,
accounting for $56,167 of the total increase.
8
<PAGE> 9
As a result of the increase in revenues, the Company has profit from
operations of $98,680 during the first two quarters, as compared to a net loss
from operations of $265,578 during the same period of the prior fiscal year.
Financial Condition
The Company has historically funded its operating expenses through loans
and sales of debt and equity securities. During the first half of fiscal 2000
the Company funded its operating expenses through revenues from sales to its UK
technology partner.
The Company presently has funds to continue operations through the third
quarter, and expects sufficient revenue through the balance of the year to fund
operations. The Company is attempting to raise additional capital. If additional
capital is not obtained by the end of September 2000, Company may be forced to
curtail operations and limit its rate of growth.
Cautionary Statements and Risk Factors
Several of the matters discussed in this document contain forward- looking
statements that involve risks and uncertainties. Factors associated with the
forward looking statements which could cause actual results to differ materially
from those projected or forecast in the statements that appear below. In
addition to other information contained in this document, readers should
carefully consider the following cautionary statements and risks factors:
Reliance on a Single Product: The Company has only one product, the MPR System.
There is no established market for this product. Accordingly, if for any reason
the MPR System cannot be marketed successfully, the Company would not survive.
Reliance on License: The Company's entire business is based on an exclusive
license of the MPR process and related technology from TRG. See "Business --
Intellectual Property." The license terminates in 2013 and may only be
terminated earlier upon the failure by the Company to observe or perform any of
its covenants, conditions or agreements contained within the license. Any
termination of the license would have a material adverse effect on the Company
and would likely result in the Company not surviving.
New and Uncertain Market: Until now, muscle injuries have always been diagnosed
and evaluated subjectively by physicians through physical examination.
Accordingly, there is no established demand for a computer assisted procedure to
assist in the diagnosis of such injuries, and it is difficult to predict if, and
when, the procedure will gain wide acceptance by prescribers. A prerequisite to
success will be the ability of the Company to establish MPR as a standard
medical practice for use in the diagnosis of muscle dysfunction. The Company
believes it will take a minimum of three to five years for such awareness to be
achieved, if it can be achieved at all. Factors that may affect market
acceptance could include resistance to change, concerns over the lack of track
record of the procedure, and the risk for insurance companies to use the results
of the procedure to challenge or overrule the diagnostic or treatment decisions
of a physician.
9
<PAGE> 10
Need for Additional Funding: To create market awareness of its MPR System, the
Company will need to devote significant resources to marketing and sales. The
Company's plan is to develop market awareness partially through a public
relations campaign, including the use of media, attendance at trade shows and
professional conferences, scientific presentations and clinical studies. In
addition, and very critical to this process, will be direct sales to providers
(including physicians, rehabilitation professionals, hospitals and diagnostic
clinics) and payors (primarily insurance companies, HMOs and PPOs). In additon
an aggressive foreign partnering program will be pursued. To fully implement its
marketing plan in 2000, the Company estimates it will need an additional $1.5
million to $2.5 million of funding beyond internally generated revenues. The
amount of funding, if any, the Company receives in 2000 will partially determine
the degree to which it can implement its marketing plan.
The Company may obtain additional funding primarily through private placements
of debt and/or equity securities with strategic partners or others. In addition,
the Company could obtain funds through development funding from and/or advance
sales to strategic partners. To date, the Company has no commitments for these
additional funds. The issuance of additional debt or equity securities by the
Company could have the effect of impairing the rights of existing shareholders.
For example, the Company could issue securities senior to the Common Stock in
liquidation (such as debt securities or preferred stock), with preferential
voting rights, or which limit or restrict the payment of dividends. In addition,
the Company could issue securities at prices that are dilutive to the existing
shareholders.
Intellectual Property: TRG holds a United States patent on the MPR technology,
and the Company is the exclusive licensee of the rights under the patent. A
second patent pertaining to the development of the MPR technology has been filed
and is pending. The inventors have assigned the rights of that patent, when
issued, to MPR. The Company believes that its ability to be successful will be
contingent on its ability to protect the MPR technology, its future developments
and its know how. There can be no assurance, however, that this patent will
provide substantial protection of the MPR technology or that its validity will
not be challenged. Pursuant to its license agreement with TRG, the Company has
the right to protect the MPR technology.
The Company presently has no patent protection of the MPR technology outside the
United States. The Company has the right to file patent applications and attempt
to obtain patents in other jurisdictions. To date, the Company has not done so,
in part because of lack of funds. TRG is under no obligation to patent the MPR
technology in any jurisdiction and the Company's determination as to whether or
not to seek patent protection will depend upon a number of factors, including
the likelihood of the issuance of the patent, the Company's financial resources
and marketing plans.
10
<PAGE> 11
Competition: The Company believes that there is no competitive diagnostic
technology in use today capable of detecting, locating and evaluating soft
tissue muscle injuries in a manner similar to the MPR System. However, there are
many companies, both public and private, which are active in the field of
medical diagnostic imaging. Some of these companies have substantially greater
financial, technical and human resources, have a well-established name and enjoy
a strong market presence. There is no assurance that one or several such
companies are not currently developing, or will not start developing, technology
that will prove more effective or desirable than the Company's technology. Such
occurrence could severely affect the Company's ability to establish and develop
a market presence and to maintain its competitive position.
Dependence on Third Parties: The success of the Company will depend, in part, on
insurance companies and managed care organizations paying for or reimbursing for
MPR evaluations. To date, over 60 insurance companies have reimbursed patients
who have been diagnosed using the MPR System. However, this has been a limited
sample in that the Company's experience is based solely on clinical tests and
test marketing. No assurance can be given as to what extent, if at all,
insurance companies will continue to reimburse for MPR evaluations.
Dependence on Key Management Personnel: The Company is substantially dependent
upon the experience of Gerald D. Appel, President, Chief Executive Officer and
founder of the Company. The loss of the services of Mr. Appel could have a
material adverse impact on the Company and its business unless a suitable
replacement for the individual is found promptly, but there is no assurance that
such replacement can be found.
Product Liability: The Company may be subject to substantial product liability
costs if claims arise out of problems associated with the use of the Company's
MPR System. While the Company maintains insurance against such potential
liabilities, there can be no assurance that such product liability insurance
will adequately insure against such risk.
Control by Management: Gerald D. Appel owns beneficially 3,685,519 shares of the
Common Stock (which includes voting rights with respect to 111,900 shares),
representing 36.7% of the outstanding voting power of the Company as of June 30,
2000. As of June 30, 2000, all directors and officers of the Company (including
Mr. Appel) currently had voting power with respect to 40.5% of the outstanding
Common Stock. Accordingly, Mr. Appel, individually, and all directors and
officers as a group, have the power to control the election of directors, and
therefore the business and affairs of the Company. See "Principal Shareholders."
This concentration of stock ownership may have the effect of delaying or
preventing a change in the management or control of the Company.
Preferred Stock: The Company is authorized to issue up to 10,000,000 shares of
Preferred Stock, issuable in one or more series, the rights, preferences,
privileges and restrictions of which may be established by the Company's Board
of Directors without stockholder approval. As a result, in the future, the
Company could issue Preferred Stock with voting and conversion rights that could
adversely affect the voting power and other rights of the holders of the Common
Stock. No shares of Preferred Stock are presently outstanding and the Company
has no present plans to issue shares of Preferred Stock.
11
<PAGE> 12
Absence of a Public Market: Presently, there is no public market for any
securities of the Company. No assurance can be given that any public market will
ever develop for any of the Company's securities. The Company does not presently
meet the requirements for listing securities on any national securities exchange
or the NASDAQ Stock Market. The absence of a public market for the Company's
securities makes an investment in such securities highly illiquid. In addition,
the absence of a public market results in there being no true "market price" for
the Company's securities which would enable investors to determine the value of
their investment.
12
<PAGE> 13
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
Nothing to report.
Item 2. Changes in Securities
Nothing to report.
Item 3. Defaults Upon Senior Securities
Nothing to report.
Item 4. Submission of Matters to a Vote of Security Holders
Nothing to report.
Item 5. Other Information
Nothing to report.
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits:
Exhibit 27.1 Financial Data Schedule
(b) Reports on Form 8-K.
None.
13
<PAGE> 14
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended, the Registrant caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
MPR HEALTH SYSTEMS, INC.
Date: August 6, 2000 By: /s/ GERALD D. APPEL
-------------------------------------------
Gerald D. Appel, President, Chief Executive
Officer and Chairman of the Board
[Principal Financial and
Accounting Officer]
